O...M...G. - that's so cool to hear. And considering our two experiences, MRKR is on the same end of the spectrum as is Qualcomm, imo. A Quality Company with a Very Bright Future.
Here is an interesting 3 minute video about how AML is no longer a death sentence, and how by teasing apart the biology there is actually a subset of cancers in AML.
And knowing the genetics and other specific characteristics, we can target it with therapies that are not as toxic as typical chemotherapy - and in fact they've changed from going from AML diagnosis-to-Chemo treatment within 24 hours to delaying it to be more tailored to the patient's particular kind of AML. (check point inhibitors, etc).
MRKR's strategy might fit well with other targeted therapies in the pre-chemo stage if it works post-chemo and post-transplant.
So, as Peter has said in the past, MRKRs therapy might become a part of a standard therapy early on in at least some cancers.
(((I should STFU, how am I possibly going to be able to get filled at 67 cents on Friday if I sit here and pump and cheerlead, ffs, smdh at myself)))
News 
Market Data 
Discover 
